Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shingrix

- PMLiVE

GSK cashes in its stake in Africa’s Aspen

Sells 28.2 million shares

- PMLiVE

Grey/Ogilvy alliance wins two GSK accounts

WPP’s GO Team to lead on two antacid brands

- PMLiVE

GSK hit as darapladib flunks phase III test

Heart disease drug disappoints in late-stage trial

- PMLiVE

Electric dreams in medicine

Treating human disease with electrical impulses dates back decades, and now pharma is exploring the concept of ‘electroceuticals’ to complement drug-based therapy

- PMLiVE

GSK sets up centre to develop greener drugs

Brazil centre to focus on sustainable chemistry

- PMLiVE

China weighs heavy on GSK figures in Q3

Pharma company loses two thirds of sales in region after scandal-hit period

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

GSK hoping to file malaria vaccine next year

New phase III data backs submission plans

- PMLiVE

GSK sells off anticoagulants for £700m

South Africa-based Aspen buys rights to Arixtra and Fraxiparine

- PMLiVE

GSK’s Revolade cleared for use in hepatitis C therapy

Adds to drug’s existing thrombocytopenia indication

- PMLiVE

GSK’s Chinese sales hit by scandal, say analysts

Company estimated to have lost a third of its revenues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links